title: Intravenous immunoglobulin therapy in juvenile dermatomyositis.
abstract: To investigate the effects of intravenous immunoglobulin (IVIG) on patients of juvenile dermatomyositis (JDM), seven children with JDM were given monthly IVIG in conjunction with other treatments. The indications included disease exacerbation, inability to reduce dose of steroid, replacing cytotoxic drug because of complication and remission-induction for those with severe initial manifestations. Two patients were reported to improve slowly and maintained improved status while on a markedly reduced dose of steroid. One patient responded favorably to the first three courses only. Three patients had evident and quick responses, which could be seen as early as two or three days after the infusion. One patient failed to experience any beneficial effect by IVIG. Four initial responders had an aggravation some time after discontinuing the monthly regimen. The untoward reactions included only two occasions of fever, and another two occasions of fever associated with transient proteinuria. In conclusion, IVIG may be of value in terms of its quick, pulsatile effect and the adjuvant potential to reduce the side effect resulting from exposure to steroid or other immunosuppressive agents as well. However, its long-term efficacy is doubtful, based on this observation.
authors.affiliation: Department of Pediatrics, National Taiwan University Hospital, Taipei, R.O.C.
authors.forename: M J
authors.initials: MJ
authors.lastname: Tsai
authors.forename: C C
authors.initials: CC
authors.lastname: Lai
authors.forename: S C
authors.initials: SC
authors.lastname: Lin
authors.forename: B L
authors.initials: BL
authors.lastname: Chiang
authors.forename: C C
authors.initials: CC
authors.lastname: Chou
authors.forename: K H
authors.initials: KH
authors.lastname: Hsieh
mesh_terms: D000203:Activities of Daily Living; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D003882:Dermatomyositis / Q000201:enzymology / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003402:Creatine Kinase; D001379:Azathioprine; D011241:Prednisone